Literature DB >> 9519831

A neuroattenuated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system.

S Kesari1, T M Lasner, K R Balsara, B P Randazzo, V M Lee, J Q Trojanowski, N W Fraser.   

Abstract

Herpes simplex virus type 1 (HSV-1) variant 1716 is deleted in the gene encoding ICP34.5 and is neuroattenuated after intracranial inoculation of mice. Although the mechanism of attenuation is unclear, this property has been exploited to eliminate experimental brain tumours. Previously, it was shown that infectious 1716 was recoverable for up to 3 days after intracranial inoculation suggesting that there may be limited replication in the central nervous system (CNS). Here it is demonstrated that 1716 replicates in specific cell types (predominantly CNS ependymal cells) of BALB/c mice, using immunohistochemical, immunofluorescence, in situ hybridization and virus titration studies. While 1716-infected mice exhibited no overt signs of encephalitis, histological analysis showed a persistent loss of the ependymal lining. Thus, although ICP34.5-deficient viruses are neuroattenuated, they do retain the ability to replicate in and destroy the ependyma of the murine CNS. A detailed understanding of the mechanism(s) of neuroattenuation and limited replication could lead to the rational design of safe HSV vectors for cancer and gene therapy in the CNS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9519831     DOI: 10.1099/0022-1317-79-3-525

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

Review 1.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 2.  Herpes simplex virus-based vectors.

Authors:  Robin Lachmann
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

3.  Attenuation of herpes simplex virus neurovirulence with picornavirus cis-acting genetic elements.

Authors:  Stephanie A Campbell; Matthew Mulvey; Ian Mohr; Matthias Gromeier
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 4.  Viruses and autophagy.

Authors:  Sagar B Kudchodkar; Beth Levine
Journal:  Rev Med Virol       Date:  2009-11       Impact factor: 6.989

5.  B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells.

Authors:  R Y Chung; Y Saeki; E A Chiocca
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

6.  Ultrastructural analysis of ICP34.5- herpes simplex virus 1 replication in mouse brain cells in vivo.

Authors:  Hina Mehta; Jacqueline Muller; Nancy S Markovitz
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

7.  Differences in pathogenicity of herpes simplex virus serotypes 1 and 2 may be observed by histopathology and high-resolution magnetic resonance imaging in a murine encephalitis model.

Authors:  H C Thomas; R D Kapadia; G I Wells; A M Gresham; D Sutton; H A Solleveld; S K Sarkar; S B Dillon; R Tal-Singer
Journal:  J Neurovirol       Date:  2001-04       Impact factor: 2.643

8.  Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice.

Authors:  P Sundaresan; W D Hunter; R L Martuza; S D Rabkin
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

9.  A herpes simplex virus-derived replicative vector expressing LIF limits experimental demyelinating disease and modulates autoimmunity.

Authors:  Michaela Nygårdas; Henrik Paavilainen; Nadine Müther; Claus-Henning Nagel; Matias Röyttä; Beate Sodeik; Veijo Hukkanen
Journal:  PLoS One       Date:  2013-05-20       Impact factor: 3.240

10.  Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability.

Authors:  Edward M Kennedy; Terry Farkaly; Peter Grzesik; Jennifer Lee; Agnieszka Denslow; Jacqueline Hewett; Jeffrey Bryant; Prajna Behara; Caitlin Goshert; Daniel Wambua; Ana De Almeida; Judith Jacques; Damian Deavall; James B Rottman; Joseph C Glorioso; Mitchell H Finer; Brian B Haines; Christophe Quéva; Lorena Lerner
Journal:  Mol Ther Oncolytics       Date:  2020-08-08       Impact factor: 7.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.